Immunotherapy for rare cancers — when there is no standard treatment

It means no regimen has been established by randomised evidence for that cancer, because too few people are diagnosed with it to run such a trial. It does not mean nothing can be done. It moves the decision from a guideline table to a documented, case-by-case assessment by a tumour board.

Two very different sentences get heard as the same sentence in a consulting room. “There is no standard treatment for this” is a statement about the evidence. “There is nothing more we can do” is a statement about the patient. The first is often true for a rare cancer. The second is a much bigger claim, and it should never be accepted without asking what was actually tested and who actually looked at the file.

Rare cancers are rare one at a time and common all together. The European RARECARE surveillance work, which is the definition most often quoted, counts a cancer as rare when fewer than six new cases per 100,000 people are diagnosed each year — and on that definition roughly one in five cancer diagnoses is a rare cancer. Indian registry coverage through the ICMR National Cancer Registry Programme is improving but still thinner for uncommon subtypes, so a family here is often working with less published information than the same family would have elsewhere.

Here is the honest starting point, and it is the part most pages skip. Having a rare cancer does not by itself make anyone a candidate for immunotherapy. Immunotherapy is not a default fallback for any cancer that lacks a protocol. Eligibility runs through the biology of the tumour — through a marker found on the tissue — and not through the absence of other options. Many patients assessed on this pathway are told that immunotherapy is not indicated for them, and no assessment anywhere can promise a different answer in advance.

What changes when there is no protocol is the route, not the standard of proof. The question stops being “what does the guideline say for this organ” and becomes “what does this tumour carry, and does anything approved, trialled or reasonably justified match it”. That opens three doors, each with its own threshold: a treatment approved by biomarker rather than by organ, a clinical trial, and documented off-label use of an approved medicine. This page walks all three, in that order, because that is the order a careful team works through them.

Immunotherapy on this page means immune checkpoint inhibitors as a drug class. No medicine or brand is named, and nothing here is a recommendation to use any treatment or a promise that a particular patient will be found eligible. At CION, immunotherapy is given as day care at our centres where it is genuinely indicated, every plan is set by a tumour board rather than by a single doctor, response-assessment PET-CT is coordinated at our partner imaging centres rather than performed in-house, and any cost discussed with you is indicative, as of August 2026, and confirmed in writing before treatment starts. CION does not provide, administer or stock CAR-T or any other cell therapy; our role there is orientation and onward referral only.

It is an approval written around a marker on the tumour rather than around the organ the cancer started in. The first was granted in 2017. If a rare tumour carries a qualifying marker, that route can in principle be considered whatever the organ of origin, subject to the approval actually in force in India.

Four markers come up in this conversation. Two of them can open a tumour-agnostic route for immunotherapy. One is organ-specific and is routinely mistaken for a tumour-agnostic marker. One opens a different class of treatment altogether and is included here because families are frequently told the wrong thing about it.

One warning about approvals, because it is the single most common source of false hope in this area. An approval granted in the United States or the European Union is not automatically an approval in India. CDSCO licenses medicines indication by indication, and a tumour-agnostic indication recognised elsewhere may not carry the same status here. The right question to ask your treating team is not “is this approved” but “is this approved in India, for this indication, today”. Where the position is genuinely unclear, a good team will tell you it is unconfirmed rather than assert it either way — and the answer changes the route, because an unapproved indication becomes an off-label decision instead.

In principle, yes. A registered medical practitioner may prescribe an approved medicine outside its licensed indication where the clinical reasoning supports it. It is not routine. It should follow a tumour board decision rather than one opinion, it is documented with written informed consent, and insurers commonly decline to fund it.

Off-label means an approved, marketed medicine used outside the exact indication written on its licence. It is not an experimental drug, and it is not a clinical trial. Both of those are separate things with separate rules. Off-label use is a clinical judgement, taken on a named patient, with the reasoning recorded — and the quality of that recording is a fair proxy for the quality of the decision.

Four things belong in that record before anything is given, and you are entitled to see all four in writing:

• The reasoning. What in this tumour’s biology or in the published literature supports trying this, stated in words you can read back.
• The uncertainty. A plain statement that the use is outside the licensed indication, that the evidence is limited, and that the benefit for this patient is not known.
• The reassessment point. The date and the scan at which the decision gets reviewed — agreed before cycle one, not improvised at cycle four.
• The stop rule. What result or what side effect means this ends. A plan without a stop rule is not a plan.

Then there is the money, which nobody raises early enough. Health insurance and government scheme cover generally follow approved indications, so an off-label plan usually shifts the cost onto the family, and a pre-authorisation is more likely to be declined than approved. Ask for the full cost of a defined number of cycles plus the scans and the blood tests, in writing, before the first dose. Every figure you are given anywhere is indicative, as of August 2026. Manufacturer access, named-patient and compassionate-use programmes do exist and are worth asking about, but availability varies by molecule and by year and nobody should promise you a place on one.

Fitness still decides, exactly as it does on any other pathway. Performance status, organ function, other illnesses and the ability to reach help quickly are assessed before an off-label plan just as rigorously as before an approved one — arguably more so, because the expected benefit is less certain. Age is not the deciding factor there either, as our page on immunotherapy in elderly patients sets out. And where someone is dealing with two separate cancers at once, the sequencing question changes shape again; immunotherapy for patients with a second cancer covers that situation on its own terms.

In seven steps. Confirm the diagnosis with an expert pathology review. Check that usable tissue remains. Test the markers that decide. Take the file to a tumour board. Then work through the approved route, the trial route and the off-label route, in that order.

1. 1

   Get the diagnosis re-read

   Rare tumours are the ones most often relabelled on expert review. Ask for the blocks and slides to be reviewed by a pathologist who sees this subtype. Nothing downstream is safe if this step is wrong.

2. 2

   Find out whether tissue is left

   Marker testing needs an adequate block. Small, old or decalcified samples often fail. Better to learn that now than after three weeks of waiting for a report that cannot be produced.

3. 3

   Test the markers that decide

   Mismatch repair by immunohistochemistry, microsatellite instability by PCR, and burden and fusions on a sequencing panel. Ask for turnaround and cost first — indicative, as of August 2026.

4. 4

   Take it to a tumour board

   Ideally one that includes a pathologist and reads molecular reports. A single opinion is not the right standard for a decision with this little published evidence behind it.

5. 5

   Check the approved route first

   If a marker qualifies, ask whether that indication is approved in India today. Approved beats everything else on evidence, on documentation and on the chance of any cover.

6. 6

   Search the trial registries next

   The Clinical Trials Registry India first, then international registries, matched against the diagnosis and the marker report. Eligibility is strict, and no place can ever be promised.

7. 7

   Only then, off-label with guardrails

   Written consent, a named reassessment scan and an agreed stop rule, all fixed before cycle one. If those three are missing, the plan is not ready to start.

Steps one to four are worth doing even if the answer at the end is no. A confirmed diagnosis and a completed marker report are the two things that let any doctor, anywhere, give you a straight answer instead of a hedge — and they are the two things most often missing from the file a family brings for a second opinion.

Often near the front, not at the end. Basket trials enrol patients by biomarker rather than by organ of origin, which is how rare cancers get studied at all. A place can never be promised: eligibility is strict, slots are limited, and enrolment is decided by the trial site.

A basket trial takes one treatment and tests it across many different cancers that share a single molecular feature. For a tumour type with a few hundred cases a year nationally, that is frequently the only realistic way its treatment will ever be studied. It is also why the marker report from step three matters so much: without it, there is nothing to match a trial against.

The Clinical Trials Registry India is the national registry that studies run in India are expected to be listed on, and asking your oncologist to search it against your diagnosis and your marker results is an entirely reasonable request. Six questions are worth asking about any study before you travel for a screening visit:

• What phase is this, and what question is the study actually trying to answer?
• What are the eligibility criteria, and which one am I most likely to fail?
• How many visits, how far away, and over how many months?
• What is paid for by the study, and what is paid for by us?
• What happens if the treatment is working when the study ends?
• If I do not qualify, what does the team suggest instead?

This section is informational. CION does not recruit for any study on this page, cannot enrol anyone, and makes no claim about how well any investigational treatment works. An investigational treatment is by definition one whose benefit has not yet been established, and a trial is a way of finding that out rather than a way of obtaining something that already works.

When the assessment says the burden outweighs what can realistically be gained. Very low performance status, uncontrolled organ problems, no way to monitor or reach help quickly, or a patient who has weighed it up and does not want it. Choosing symptom control instead is an active decision, not a surrender.

An eligibility explainer that only ever points one way is not much use to a family that has already been told the worst. These are the questions worth asking out loud, and a team that answers all six honestly is giving you a framework rather than a sales pitch.

• What is this treatment realistically aiming to do — control the disease, relieve a symptom, or buy time to reassess?
• What would happen if we treated the symptoms well and gave no immunotherapy at all?
• How certain is the evidence behind this particular plan, in plain words?
• How many hospital visits does it involve, and is that how these months should be spent?
• Who is at home to notice a change and act on it the same day?
• What exactly would make us stop, and who makes that call?

There are also situations where the pathway is genuinely different rather than simply harder. Pregnancy is one of them, and the assessment there follows its own rules; our page on immunotherapy during pregnancy sets those out. In every one of these situations the decision belongs to a team that has read the whole file, and the patient’s own view belongs in the room while it is being made, not afterwards.

Supportive and palliative care is active treatment rather than the absence of it. It can run alongside a decision to treat just as easily as it can replace one, and for a rare cancer with thin evidence behind every option, it is often the part of the plan that changes how the next few months actually feel.

A rare diagnosis is one variable inside a larger eligibility question. These pages cover what families ask next: what a second cancer changes, how pregnancy alters the assessment, why age is not the deciding factor, and where immunotherapy fits at CION at all.

• Immunotherapy for Patients With a Second Cancer — how sequencing and eligibility are worked out when two separate cancers are in the picture at the same time.
• Immunotherapy During Pregnancy — why this is one of the few situations where the pathway itself is different, and how the assessment is handled.
• Immunotherapy in Elderly Patients: Is Age a Barrier? — performance status and frailty rather than the birth year, and why an age alone is never the reason.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is delivered as day care, how response scans are coordinated with our partner imaging centres, and how costs are set out in writing.

If you have been told there is no standard treatment, bring three things: the pathology report with the block details, any marker testing already done, and the list of what has already been tried. That is enough for a tumour board to give you a real answer rather than a hedge — including a plain no, if that is what the file supports.

This page is general information and does not replace a consultation. It describes a treatment class only, names no medicine or brand, recommends no treatment, and does not promise that any patient will be found eligible or that any trial place will be available. Marker definitions, tumour-agnostic indications and testing recommendations are drawn from NCCN, ESMO and ASCO patient-education guidance current in August 2026, and regulatory status in India is set by CDSCO and changes over time, so it must be confirmed with your treating team. No survival figure or outcome percentage is stated or implied anywhere on this page. CION Cancer Clinics does not provide, administer or stock CAR-T or any other cell therapy. Every decision about assessment, treatment and its alternatives belongs with your own treating team.

Before you accept that nothing more can be done

Free, 45 minutes, reviewed by a tumour board. Bring the pathology report, the block details and whatever has already been tried.